Revvity Raclopride, -, 250uCi (9.25MBq)

Raclopride is a synthetic compound that acts as a selective antagonist at dopamine D₂ receptors. These receptors are potential drug targets for schizophrenia, Parkinsons disease, and other neurological conditions.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET975:

1. Sørensen, g., Sager, T.N., Petersen, J.H. et Al. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice, Psychopharmacology (2008) 199: 37-46.
2. Chen, J., Su, H., Huang, L., Hsieh, M. Reductions in binding and functions of D2 dopamine receptors in the rat ventral striatum during amphetamine sensitization, Life Sciences (1998) 64 (5): 343-354.